Trial Profile
ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naive Adults Starting Treatment for Rifampicin-sensitive Tuberculosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRING
- Sponsors ViiV Healthcare
- 23 Sep 2020 Results (n = 42) assessing population pharmacokinetic analysis of Efavirenz in antiretroviral therapy-naive adults, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 15 Apr 2020 Status changed from active, no longer recruiting to completed.
- 20 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.